Back
Top 0.2%
23.8%
#1
12.7%
Top 0.4%
11.8%
Top 59%
10.0%
Top 0.7%
4.1%
Top 71%
3.3%
Top 2%
3.3%
Top 0.9%
3.3%
Top 35%
2.1%
Top 47%
2.1%
Top 8%
2.1%
Top 19%
2.1%
Top 7%
1.7%
Top 8%
1.3%
Top 6%
1.2%
Top 1%
0.8%
Top 5%
0.8%
A Phase Ib/II multi-arm, dose finding and expansion study of a novel thymidylate synthase inhibitor with immune modulating properties, NUC-3373, in combination with pembrolizumab or docetaxel in patients with advanced solid tumors (NuTide:303)
2024-11-08
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundNUC-3373 is a novel thymidylate synthase (TS) inhibitor designed to directly deliver the active anti-cancer metabolite fluorodeoxyuridine-monophosphate (FUDR-MP or FdUMP) intracellularly. In addition to being a potent TS inhibitor, NUC-3373 has also been shown to cause DNA damage and promote the release of damage-associated molecular patterns. These diverse mechanisms position NUC-3373 as a potentially effective combination partner for several other anti-cancer agents. MethodsNuTide:3...
Predicted journal destinations
1
Cancers
57 training papers
2
Clinical Cancer Research
22 training papers
3
Frontiers in Oncology
34 training papers
4
PLOS ONE
1737 training papers
5
Cancer Medicine
17 training papers
6
Scientific Reports
701 training papers
7
British Journal of Cancer
22 training papers
8
BMC Cancer
21 training papers
9
Nature Communications
483 training papers
10
BMJ Open
553 training papers
11
JAMA Network Open
125 training papers
12
eLife
262 training papers
13
Frontiers in Immunology
140 training papers
14
Nature Medicine
88 training papers
15
Heliyon
57 training papers
16
International Journal of Cancer
18 training papers
17
Journal of Clinical Investigation
50 training papers